(Q40145370)

English

Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?

scientific article published on February 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise? (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

5

object named as

Mitch Dowsett

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Stephen R D Johnston

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Alexandra Leary

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Lesley-Ann Martin

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ian E Smith

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

0 references

publication date

1 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

112

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

3 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

710-717

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of PI3K/Akt signaling and hormone resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Aberrant function of the Ras signal transduction pathway in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of farnesyl transferase inhibitors: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23190

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23190

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40145370&oldid=2213567109"